Company intelligence / Profile preview

Aten Porus Lifesciences

Bangalore (Bengaluru), Karnataka, Indiaatenporus.com ↗

Ownership: Private
Employees: ~39
Development stage: Preclinical

Overview

The company is developing novel small molecule drugs that can be administered orally. Their lead assets are being investigated for cancer and autoimmune diseases. One of their spinoffs, Oraxion Therapeutics, has demonstrated therapeutic efficacy of their lead compound ORX-301 in preclinical models for NPC and FSGS.

Therapeutic areas: OncologyRare DiseasesImmunologyNephrologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Partnerships

Oraxion entered into a $125 million option-to-license agreement with a US biopharmaceutical company in 2018

Beyond the preview

Go deeper on Aten Porus Lifesciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aten Porus Lifesciences.

Explore the full profile